Csl Behring News Today

Watch. Erik time for our top stories is one of his best begin with this. German chancellor Angela Merkel is standing out optimism in the greek crisis. They end the night with the leaders of greece in france. Greece once the remaining 8 billion in bailout funds to the void avoid the fall. She says there is a whole lot more to do before that can happen. I will have bilateral talks and have hardly spoken last night with the french president and the greek Prime Minister. It was a very friendly, cons...

/PRNewswire/ -- CSL Behring, a business unit of global biotechnology leader CSL, today announced survey results showing that the majority of surveyed people...

Investigators propose potential payment models for gene therapies that consider equitable patient access and payer reimbursement.

Nonunion dockworkers blocked entrances to Mexico’s Lazaro Cardenas Port while dockers across Chile staged a 72-hour strike and 700 pharmaceutical workers in Illinois have ratified a contract.

Gene therapy company uniQure N.V. (QURE) announced Monday it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX (etranacogene dezaparvovec-drbl) to HealthCare Royalty (HCRx) and Sagard Healthcare for a gross purchase price of up to $400 million in cash.

Dublin, March 02, 2023 (GLOBE NEWSWIRE) -- The "Global Markets for Blood Plasma Products" report has been added to ResearchAndMarkets.com's offering. ...

MARBURG, GERMANY Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for hemophilia B to patients in Europe.

MELBOURNE, AUSTRALIA The Board of Directors of CSL Limited today announces that it has appointed Dr. Paul McKenzie as Chief Executive Officer (CEO) and Managing Director of CSL from 6 March 2023.

DUBLIN--(BUSINESS WIRE)--The "Global Immunoglobulin Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.This report suggests that the global immunoglobulin market would exhibit an uptrend trend at a CAGR of 6.77% over the forecast period of 2022-2028.The market's growth is supported by drivi...

US regulators approved CSL Behring’s haemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5m a dose, making it the most expensive medicine in the world.